{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T17:06:32Z","timestamp":1654967192568},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.leukres.2012.03.016","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T13:40:57Z","timestamp":1334238057000},"page":"803","source":"Crossref","is-referenced-by-count":3,"title":["Towards a need to a \u201cbiological Sokal risk\u201d in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia"],"prefix":"10.1016","volume":"36","author":[{"given":"Fabio","family":"Stagno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.03.016_bib0005","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.03.016_bib0010","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.03.016_bib0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.03.016_bib0020","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European leukemianet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.03.016_bib0025","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.016_bib0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2012.03.016_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1470-2045(10)70258-8","article-title":"Who is in charge of assessing therapeutic drug monitoring? The case of imatinib","volume":"12","author":"Buclin","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2012.03.016_bib0040","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0950-3536(87)80032-X","article-title":"Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment","volume":"1","author":"Sokal","year":"1987","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.leukres.2012.03.016_bib0045","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.03.016_bib0050","series-title":"Blood (ASH Annual Meeting Abstracts)","article-title":"BCR-ABLIS expression at diagnosis and after 3 or 6 months of treatment predicts CML response to IMATINIB therapy","author":"Vigneri","year":"2010"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612001397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612001397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T05:27:04Z","timestamp":1543037224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612001397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0145212612001397"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.03.016","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}